Welcome to LookChem.com Sign In|Join Free
  • or
(S)-1-<(tert-butyldiphenylsilyl)oxy>-3-(tosyloxy)-2-propanol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

125111-29-7

Post Buying Request

125111-29-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

125111-29-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 125111-29-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,1,1 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 125111-29:
(8*1)+(7*2)+(6*5)+(5*1)+(4*1)+(3*1)+(2*2)+(1*9)=77
77 % 10 = 7
So 125111-29-7 is a valid CAS Registry Number.

125111-29-7Downstream Products

125111-29-7Relevant academic research and scientific papers

Synthesis and β-Adrenergic Antagonist Activity of Stereoisomeric Practolol and Propranolol Derivatives

Leftheris, Katerina,Goodman, Murray

, p. 216 - 223 (2007/10/02)

A series of stereoisomeric practolol and propranolol derivatives has been synthesized in which the N-isopropyl group of the drug was replaced by an asymmetric heptanoic acid terminated by a substituted p-toluidide of p-(tri-fluoromethyl)anilide.The asymmetric epoxide, 3-(p-acetamidophenoxy)-1,2-epoxypropane, was allowed to react with a preformed enantiomeric 6-aminoheptanoic acid amide to yield the stereoisomeric practolol congener derivatives.An asymmetric drug precursor epoxide was prepared from p-acetamidophenol and enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide).For the propranolol congener derivatives, the preformed asymmetric 6-aminoheptanoic acid amides were allowed to react with one of the enantiomers of 3-(1-naphthyloxy)-1,2-epoxypropane.This drug precursor epoxide was prepared either by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide) or by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-propanediol followed by epoxidation.Pharmacological studies carried out for the practolol derivatives demonstrated a significant dependence of enhanced potency and tissue/subreceptor specificity on both the configuration of the drug asymmetric carbon and the configuration of the spacer asymmetric carbon.The compounds containing the S configuration at the drug asymmetric center and the R configuration at the spacer asymmetric carbon exhibited an increase in potency over the other stereoisomeric congener derivatives and the progenitor drug.For the propranolol congener derivatives, a large decrease in potency was observed for all of the stereoisomers over the progenitor drug.The propranolol stereoisomers containing the S configuration at the drug asymmetric center were more active than those containing the R configuration at that center.

A Facile Synthesis of (S)-3-Tosyloxy-1,2-propanediol from (S)-2,2-Dimethyl-1,3-dioxolane-4-methanol

Leftheris, Katerina,Goodman, Murray

, p. 564 - 565 (2007/10/02)

(S)-3-Tosyloxy-1,2-propanediol has been synthesized from (S)-2,2-dimethyl-1,3-dioxolane-4-methanol in four steps with an overall yield of 87percent.This coupled with the existing method in the literature for the conversion of (S)-1 to (R)-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 125111-29-7